Loading ...
Sorry, an error occurred while loading the content.

Sirna Therapeutics Demonstrates Systemic Efficacy of siRNAs in Multiple Animal

Expand Messages
  • Patricia (Alley)
    The Company is using HBV as a surrogate model of hepatitis C (HCV) infection. Based on these groundbreaking results the Company expects to select an HCV
    Message 1 of 1 , Jun 8, 2004
    • 0 Attachment
      The Company is using HBV as a surrogate model of hepatitis C (HCV) infection. Based on these groundbreaking results the Company expects to select an HCV clinical candidate by the end of this year.


      http://biz.yahoo.com/prnews/040607/lam074_1.html

      [Non-text portions of this message have been removed]
    Your message has been successfully submitted and would be delivered to recipients shortly.